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Background: Gene silencing of the repair genes MLH1 and MGMT was shown to be a mechanism underlying the
development of microsatellite instability (MSI), a phenotype frequently associated with various human malignancies.
Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such
as BRAF, RAS and IDH1 in colon and brain tumours. Little is known about the methylation status of MLH1 and MGMT
in thyroid tumours and its association with MSI and mutational status.
Methods: In a series of 96 thyroid tumours whose mutational profiles of BRAF, IDH1 and NRAS mutations and
RET/PTC were previously determined, we investigated MLH1 and MGMT expression and methylation status by qPCR
and methylation-specific PCR after bisulphite treatment, respectively. MSI was determined by PCR using seven
standard microsatellite markers.
Results: Samples with point mutations (BRAF, IDH1 and NRAS) show a decrease in MLH1 expression when
compared to negative samples. Additionally, malignant lesions show a higher MSI pattern than benign lesions.
The MSI phenotype was also associated with down-regulation of MLH1.
Conclusions: The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF
V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.
In addition, a significant relationship between MSI status and histological subtypes was found.
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Thyroid cancer is the most common type of endocrine
cancer. Its worldwide incidence has more than doubled
since the 1970s. In fact, thyroid cancer is the fastest-
growing number of new cancer cases in women [1]. Papil-
lary Thyroid Carcinoma (PTC) is the most common
subtype, representing approximately 80% of cases. Follicular
Thyroid Carcinoma (FTC) is the second most prevalent
subtype, accounting for 10-15% of thyroid cancers [1-4].
Multiple genetic and epigenetic alterations have been
described in thyroid cancers in recent decades. Most
mutations involve effectors of the mitogen-activated pro-
tein kinase (MAPK) and phosphatidylinositol 3-kinase* Correspondence: marcelo.ribeiro@usf.edu.br
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reproduction in any medium, provided the or(PI3K) pathways. Mutations in RET/PTC, RAS, or BRAF,
which result in constitutive MAPK signalling, are found
in approximately 70% of PTC cases with little overlap
between mutated genes. BRAF V600E is the most com-
mon genetic alteration found in PTC, with a worldwide
prevalence of 29 to 83% [5-9]. RET/PTC rearrangements
are the second most common genetic alteration found in
PTC. A highly variable rate of RET/PTC rearrangement
has been reported in different studies; the rate ranges
from as low as 0% to as high as 87% [10,11]. Genetic
alterations in the PI3K/Akt pathway are more commonly
found in the genesis and progression of FTC. PIK3CA
mutations and amplification were found in FTC. Add-
itionally, PI3K can be activated through genetic or epi-
genetic inactivation of PTEN. Finally, the PI3K pathway
can be activated through acquisition of RAS or PAX8/
PPAR gamma mutations.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primers used in this study
Marker or gene Primer (50-30)
BAT-25 FW -TCGCCTCCAAGAATGTAAGT
RV - TCTGCATTTTAACTATGGCTC
BAT-26 FW -TGACTACTTTTGACTTCAGCC
RV -AACCATTCAACATTTTTAACCC
D5S346 FW -ACTCACTCTAGTGATAAATCG
RV-AGCAGATAAGACAGTATTACTAGTT
BAT40 FW -GTAGAGCAAGACCACCTT
RV - AATAACTTCCTACACCACAAC
D2S123 FW -AATGGACAAAAACAGGATGC
RV -CCCTTTCTGACTTGGATACC
D11S912 FW -TACTGCTTTGGGTATGCATATG
RV -GCTTTTTGTCTAGCCATGATTG
D17S250 FW -GGAAGAATCAAATAGACAA
RV -GCTGGCCATATATATATTTAAACC
MGMT FW - CACCACACTGGACAGCCCTTT
RV - CGAACTTGCCCAGGAGCTTTATTT
MLH1 FW -AGAGTGGCTGGACAGAGGAA
RV -CCCTTCCTCATCAATTTCCA
RPS8 FW -AACAAGAAATACCGTGCCC
RV -GTACGAACCAGCTCGTTATTAG
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mutation occurs in approximately 48% of PTC cases
[7,8]. RET/PTC rearrangements were found in nearly
45% of PTC cases in Brazil (submitted). PIK3CA and
RAS mutations were rarely found in our series [12]. Re-
cently, our group [12] and others [13,14] described
mutations in the IDH1 (isocitrate dehydrogenase 1)
gene; these mutations were mainly associated with
the pathogenesis of the follicular variant of PTC
(FVPTC) and FTC but were rarely found in classical
PTC.
Microsatellite instability (MSI), caused by defects in the
mismatch repair pathway, is a phenotype frequently
associated with various human malignancies. Interes-
tingly, promoter hypermethylation of the mismatch re-
pair gene Human Mut-L Homologue 1 (MLH1) was
previously associated with MSI and the presence
BRAF V600E mutations in colon cancer [15]. Additi-
onally, hypermethylation of O6-methylguanine DNA
methyltransferase (MGMT), a DNA repair protein that
prevents G:C >A:T point mutations by removing alkyl
adducts from the O6 position of guanine, may lead to IDH1
and RAS mutations in gliomas. Others have described that
loss of MGMT expression may lead to PIK3CA mutations
[15]. Whether promoter hypermethylation of the MLH1
and MGMT genes is the underlying mechanism associated
with presence of BRAF V600E, RAS, IDH1, PIK3CA
mutations and/or other genetic alterations found in thyroid
tumours is still unknown.
In this study, we investigated the methylation status of
MLH1 in a series of benign and malignant thyroid
lesions. We next correlated MLH1 methylation status
with expression of MLH1, MSI and mutational status.
Additionally, as most IDH1 and RAS mutations found in
our series of thyroid carcinomas were transitions [12]
and considering that an association between MGMT and
transitions exists, we assessed whether the presence of
IDH1 and RAS mutations is associated with MGMT
methylation and/or loss of MGMT expression.
Methods
Thyroid samples
A total of 96 thyroid tissue samples obtained from
patients who underwent thyroid surgery for thyroid can-
cer at Hospital São Paulo, Universidade Federal de São
Paulo and Hospital das Clínicas, Universidade Estadual
de São Paulo was used in this study. All tissue samples
were obtained with informed consent according to
established human studies protocols at Federal Univer-
sity of São Paulo (protocol 1259/11). To enrich the
samples for tumour cells, tissue specimens were
obtained from the central part of the tumour specimens.
This strategy avoids contamination with surrounding
normal tissue and allows for proper pathologicaldiagnosis. Specimens were frozen in liquid nitrogen im-
mediately after surgical resection and stored at −80°C.
Final histological classification was obtained from
paraffin-embedded sections. The study included 70
PTCs, 12 FTCs, 7 benign follicular thyroid adenomas
(FTAs) and 7 adjacent normal thyroid tissues.
All samples were previously tested for BRAF, NRAS
and IDH1 mutations [7,8,12]. RET/PTC rearrangements
were investigated in 56 PTC samples for which RNA
was available (submitted).
Real-time PCR
For MLH1 and MGMT expression analysis, total RNA
was isolated using Trizol reagent as described previously
(Invitrogen Corporation, Carlsbad, CA, USA) [16]. RNA
isolation and cDNA synthesis were performed as previ-
ously reported [16,17]. Aliquots of 1 μL of cDNA were
used in 12-μL reactions containing SYBRW Green Master
Mix (PE Applied Biosystems, Foster City, CA) and
200–250 nM of each primer for the target genes and
reference gene (RPS8), as described previously [17]. The
primer sequences are described in Table 1.
The reactions were performed in triplicate using a 7500
Real-Time PCR System (PE Applied Biosystems). The
threshold cycle (Ct) for each reaction was obtained using
Applied Biosystems Software, and the values were averaged
(SD ≤ 1). The PCR efficiencies for RPS8, MLH1, and
MGMT were 1.0, 0.99 and 1.0, respectively (data not
shown). As PCR efficiencies were comparable, relative
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(ddCt formula) as described previously [8,17].
DNA extraction and bisulphite treatment
A portion of each tissue was used for the extraction of
genomic DNA, which was performed using an adapted
phenol-chloroform procedure. One microgram of DNA
was treated with sodium bisulphite to convert cytosine to
uracil using the EpiTectW Bisulfite kit (QIAGEN,
Valencia, CA, USA) according to the manufacturer's
recommendations. Briefly, the conversion was made using
the following thermal profile: 5 minutes at 95°C, 25
minutes at 60°C, 5 minutes at 95°C, 85 minutes at 60°C, 5
minutes at 95°C, 175 minutes at 60°C and storage at 20°C.
The DNA samples were purified, and bisulphite-treated
DNA was resuspended in 30 μL of elution buffer for gene
methylation analysis.
DNA methylation analysis
DNA methylation was detected using methylation–
specific PCR (MSP) performed with a primer set specific
to the methylated or un-methylated sequence (M or U
sets, respectively) [18]. The PCR reactions were
performed in a final volume of 25 μL, containing ap-
proximately 200 ng of sodium bisulphite-treated DNA
and 25 pmol of each primer. The PCR amplifications
were performed for 30 cycles and consisted of a denatur-
ation step of 95°C for 5 min, a primer-annealing step of
58°C for 35 sec and an extension step at 72°C for 40 sec,
with a single final extension step of 72°C for 7 min. The
reaction products were separated by electrophoresis on
8% polyacrylamide gels and visualised by silver staining.
Microsatellite instability analysis
We analysed the microsatellite instability pattern using
7 standard microsatellite markers, of which 3 were
mononucleotide repeats (BAT25, BAT26 and BAT40) and
4 were dinucleotide repeats (D2S123, D11S912, D2S346
and D17S250). The MSI analysis was performed by PCR
using specific primers (Table 1). PCR was carried out in a
total volume of 20 μL, containing 200 ng of DNA, 2.5 μL
of 10X PCR Buffer, 1 μM primer, 1.5-2.0 mM MgCl2, 200
μM dNTPs and 0.5 U of Taq polymerase (Invitrogen); the
products were amplified by 1 cycle of 95°C for 5 min
followed by 35 cycles of 95°C for 30 s, 55–58°C for 30 s
and 72°C for 15 s, with a final extension at 72°C for 1 min.
After the reaction, the samples were denatured using
single-strand conformation polymorphism (SSCP) by
heating at 95°C for 10 min, and gel electrophoresis was
performed on the PCR-amplified products using a 6%
polyacrylamide gel containing 6 M urea.
To assess MSI, we compared the band pattern
produced after gel electrophoresis of paired PCR
reactions containing patient-matched normal and tumourDNA. If the normal and tumour (benign or malignant)
PCR amplification products displayed different electro-
phoretic motilities, the case was scored as positive for
MSI. Samples showing instability at one locus were scored
as MSI-Low (MSI-L), and those showing instability at two
or more loci were scored as MSI-High (MSI-H).
Statistical analysis
Categorical data were summarised using frequencies and
percentages. The relationship between the mutation,
methylation and MSI statuses in PTC, FTC or benign
subgroups was determined using Fisher’s exact test. Stat-
istical analysis was performed within each subgroup.
For expression analysis, normality was verified using
the Shapiro-Wilk normality test. Because the data were
not normally distributed, non-parametric statistics were
used. A Mann–Whitney test was performed to evaluate
the relationship between the expression of MLH1 or
MGMT and mutational status (mutant or wild-type) and
to evaluate the relationship between MSI or MSS in
PTC, FTC or benign subgroups. P values <0.05 were
considered significant. The SPSS software (version 11.5;
SPSS Inc., Chicago, IL, USA) was used for data analysis.
Results
Samples
Of the 82 malignant samples, a BRAF V600E mutation
was observed in 29 of 70 (41%) PTC samples. No BRAF
V600E mutations were found in the 12 FTC samples
(0%). RET/PTC was observed in 25 of 56 (45%) PTC
samples. IDH1 mutations were observed in 5 of 70 (7%)
PTC samples and 4 of 12 (33%) FTC samples. NRAS
mutations were observed in 3 of 70 (4%) PTC samples
and 3 of 12 (25%) FTC samples. No mutations were
found in the benign group.
Expression of MLH1 was lower in mutated thyroid
carcinoma
In this study, the promoter methylation patterns of two
DNA repair genes, MHL1 and MGMT, were evaluated in
thyroid samples. In the PTC group, the data showed that
MLH1 and MGMT were methylated in 44% and 64% of
the cases, respectively. A similar pattern was observed in
the FTC subgroup. No significant difference was observed
between benign and FTC or PTC samples (Table 2).
We also evaluated the relationship between promoter
methylation and presence of specific mutations. For this
analysis, we defined negative as those samples that proved
to be negative for the panel of mutations, i.e., BRAF
V600E, NRAS Q61R, IDH1 mutations and RET/PTC
rearrangements. The negative subgroup comprises 19 of
70 (27%) PTC and 6 of 12 (50%) FTC samples. Samples
harbouring more than one mutation (n = 10) were also
excluded from statistical analysis.
Table 2 Association between methylation patterns of MLH1 and MGMT and histological subtypes
Methylation status PTC (n = 70) FTC (n = 12) Benign (n = 14)
N (%) p* N (%) p* N (%)
MLH1 Methylated 31/70 (44%) 0.242 4/12 (33%) 0.238 9/14 (64%)
Unmethylated 39/70 (56%) 8/12 (67%) 5/14 (36%)
MGMT Methylated 45/70 (64%) 0.763 8/12 (67%) 0.701 8/14 (57%)
Unmethylated 25/70 (36%) 4/12 (33%) 6/14 (43%)
*p values compared against benign group.
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MLH1 expression in samples harbouring BRAF V600E mu-
tations (Figure 1A), RET/PTC rearrangements (Figure 1B),
or transitions (Figure 1C). However, when samples with
point mutations were grouped together, MLH1 expression
was significantly decreased (p = 0.019; Figure 1D). No sig-
nificant relationship was found between MGMT expres-
sion levels and the mutations.
Despite the decreased expression observed, BRAF
V600E-mutated samples had a hypomethylated pattern
(p = 0.048). No significant relationship was found be-
tween MGMT methylation and the mutations (Table 3).Figure 1 Relative expression of MLH1 and MGMT in thyroid cancer sa
rearrangements (B), samples with IDH1 and NRAS transitions (C) or al
mutations and RET/PTC were only performed for the PTC group, as these a
only the samples without any of the alterations investigated. The symbols
Y-axis indicates the relative expression values of MLH1, and the right Y-axis
indicated if statistically significant.Malignant lesions show a higher pattern of MSI
Microsatellite instability analysis showed that 37% of the
samples were positive for the D17S250 microsatellite in-
stability marker, 34% for D2S346, 19% for D2S123, 12%
for D11S912, 10% for BAT40, 10% for BAT26 and 2%
for BAT25.
Our data showed that 84% (59/70) of PTC samples had
MSI. Among them, 64% (38/59) showed a MSI-H pattern
and 46% (21/59) a MSI-L pattern. In the FTC group, 92%
(11/12) of samples had MSI; 82% (9/11) were MSI-H and
18% (2/11) were MSI-L. In the benign group, no MSI-H
was observed; all MSI positive samples (43% - 6/14) weremples according to mutational status of BRAF V600E (A), RET/PTC
l samples with point mutations (D). Analyses of BRAF V600E
lterations are exclusive of this subtype. The negative group comprises
represent the mean, and the lines represent the standard error. The left
indicates the relative expression values of MGMT. The p values are
Table 3 Association between methylation patterns of
MLH1 and MGMT and mutational status
Methylation status Mutational status N (%) p
BRAF V600E*
MLH1 Methylated Positive 4/20 (20%) 0.048
Negative 10/19 (53%)
Unmethylated Positive 16/20 (80%)
Negative 9/19 (47%)
MGMT Methylated Positive 14/20 (70%) 0.333
Negative 10/19 (53%)
Unmethylated Positive 6/20 (30%)
Negative 9/19 (47%)
RET/PTC*
MLH1 Methylated Positive 8/16 (50%) 1.000
Negative 10/19 (53%)
Unmethylated Positive 8/16 (50%)
Negative 9/19 (47%)
MGMT Methylated Positive 9/16 (56%) 1.000
Negative 10/19 (53%)
Unmethylated Positive 7/16 (44%)
Negative 9/19 (47%)
Transitions (IDH1 + NRAS)
MLH1 Methylated Positive 5/11 (45%) 1.000
Negative 13/25 (52%)
Unmethylated Positive 6/11 (55%)
Negative 12/25 (48%)
MGMT Methylated Positive 9/11 (82%) 0.268
Negative 15/25 (60%)
Unmethylated Positive 2/11 (18%)
Negative 10/25 (40%)
Point mutations (BRAF + IDH1 + NRAS)
MLH1 Methylated Positive 14/41 (34%) 0.199
Negative 13/25 (52%)
Unmethylated Positive 27/41 (66%)
Negative 12/25 (48%)
MGMT Methylated Positive 29/41 (71%) 0.426
Negative 15/25 (60%)
Unmethylated Positive 12/41 (29%)
Negative 10/25 (40%)
* Analysis performed only in the PTC group.
Negative group comprises only samples without any of the
alterations investigated.
Table 4 Relationships between mutations and MSI patterns
by histological subtype
MSI
status
PTC FTC Benign
N (%) p* N (%) p* N (%)
MSI 59/70 (84%) 0.002 11/12 (92%) 0.012 6/14 (43%)
MSI-H 38/59 (64%) 9/11 (82%) -
MSI-L 21/59 (46%) 2/11 (18%) 6/6 (100%)
* p values compared against the benign group.
Table 5 Relationships between mutations and MSI patterns
Mutation status N (%) p
BRAF V600E*
Positive 18/20 (90%) 1.000
Negative 17/19 (89%)
RET/PTC*
Positive 13/16 (81%) 0.642
Negative 17/19 (89%)
Transitions (IDH1 + NRAS)
Positive 9/11 (82%) 0.631
Negative 22/25 (88%)
Point mutations (BRAF + IDH1 + NRAS)
Positive 35/41 (85%) 1.000
Negative 22/25 (88%)
* Analysis performed only in the PTC group.
Negative group comprises only samples without any of the alterations investigated.
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patterns between PTC and FTC compared with the benign
group was observed (Table 4). Furthermore, no relationship
was observed between MSI and any mutations (Table 5).
Relationship of MGMT and MLH1 expression, methylation
and MSI
Regarding the effects of MLH1 and MGMT expression on
MSI status, our data showed that the MSI phenotype
correlated with down-regulation of MLH1 among patientswith benign lesions compared with samples with MSS.
Similar results were also observed for MGMT (Figure 2A
and 2B). As the FTC group only had one sample with
MSS, the statistical analysis could not be performed.
Although MSI status was not correlated with MLH1
expression levels in PTC, we found a marginal associ-
ation between MSI and MLH1 methylation in the PTC
group (p = 0.079). The methylation pattern of MGMT
was associated with MSI in PTC samples (p = 0.01;
Table 6).
Discussion
DNA repair mechanisms are essential for correcting post-
replication errors. Impaired DNA repair is related to
increases in mutation frequency, genomic instability and
cell death. Aberrant DNA methylation and expression silen-
cing is an important molecular alteration that is commonly
detected in DNA repair genes in different types of cancer.
Because MLH1 promoter methylation was previously
associated with MSI and a BRAF V600E mutation [19],
we tested the methylation status of MLH1 in a series of
thyroid tumours and correlated them with mutational
status and MSI. Additionally, a previous study has
reported that MGMT hypermethylation was associated
with transitions in IDH1 and RAS [20]. Thus, we
assessed whether the presence of IDH1 and RAS
mutations is associated with MGMT methylation and/or
loss of MGMT expression.
Figure 2 Relative expression of MLH1 (A) and MGMT (B) in samples according to MSI and MSS pattern and histological subtype. The
symbols represent the mean, and the lines represent the standard error.
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and MGMT promoter methylation between the groups
studied. This result suggests that mechanisms other than
DNA methylation in the CpG island studied, e.g., methy-
lation in other CpG islands, miRNAs and histone
modifications, could be acting to silence the expression
of the genes studied.
The putative relationships between MLH1 expression
and BRAF V600E, RET/PTC and IDH1 genetic alterations
were evaluated. Our results showed diminished expression
of MLH1 in patients harbouring BRAF V600E mutations,
RET/PTC rearrangements and transitions (IDH1 and
NRAS). Although not significant, this result suggests a
trend toward significance. Studying a larger set of samples
may provide a more detailed understanding of this issue. In
fact, when all samples with point mutations were grouped
together, a significant association was found. To the best of
our knowledge, this evidence is the first to indicate that the
down-regulation of MHL1 is related to BRAF V600E
mutations, RET/PTC rearrangements and transitions
(IDH1 and NRAS) in patients with thyroid carcinoma.
We did not find a significant correlation between
MGMT hypermethylation and/or loss of expression and
its association with mutational status. A larger sample
set may be necessary to reject the hypothesis that
MGMT hypermethylation or loss of expression is not
associated with IDH1 or RAS mutations. Interestingly,
the primary mutation found in IDH1 brain tumours was
at codon R132, while in thyroid carcinomas, non-R132
mutations were found [12].
Microsatellite instability is a hallmark of the mismatch
repair (MMR) deficiency [21,22]. Thus, to evaluate theTable 6 Analysis of MSI and MLH1 or MGMT methylation
Methylated
and MSI
PTC FTC Benign
N (%) N (%) N (%)
MLH1 24/31 (77%)* 3/4 (75%) 4/9 (44%)
MGMT 38/45 (84%)** 7/8 (87%) 3/8 (37%)
*p = 0.079 compared with the benign group; **p = 0.01.MSI status of the thyroid samples, we used seven markers.
The microsatellite markers demonstrating the highest fre-
quency of MSI were D17S250, D2S346 and D2S123. The
lowest frequencies were observed for BAT40, BAT26 and
BAT25. Furthermore, mononucleotide markers (BAT40,
BAT26 and BAT25) present the lowest frequency of in-
stability among all microsatellite markers tested for both
benign and malignant thyroid tumours [23,24].
A significant relationship between MSI status (MSI-H)
and histological subtypes was demonstrated in both PTC
and FTC, and a higher frequency was found in patients
with FTC. MSI is related to malignancy and the
clinicopathological factors that indicate poor prognosis
[23-25]. MSI does not act as an early event in thyroid
tumourigenesis, but MSI is instead involved in tumour
progression [24], indicating that MSI might play an im-
portant role in thyroid carcinogenesis, as previously
described [23-26]. We evaluated the relationship between
each mutation and the MSI pattern. Although the BRAF
V600E mutation has been associated with sporadic MSI-H
colorectal cancers [27], no relationship was found between
BRAF V600E mutations, RET/PTC rearrangements and
transitions (IDH1 and NRAS) and MSI status.
Although it has been suggested that in thyroid
tumours, MSI is an important indicator of defects in the
MMR system [28], the data presented in this study
showed no relationship between MLH1 expression and
MSI status. In addition, a previous study on colorectal
cancer showed that methylation of another DNA repair
gene, MGMT, is also linked to MSI [22,29]. In thyroid
samples, our data showed a relationship between pro-
moter methylation and MSI phenotype.
Conclusions
Taking these facts into consideration, the results of this
study allow us to conclude that low expression of MLH1
is associated with BRAF V600E mutations and RET/
PTC rearrangements and transitions (IDH1 and NRAS)
in patients with thyroid carcinoma. Furthermore, a
Santos et al. BMC Cancer 2013, 13:79 Page 7 of 7
http://www.biomedcentral.com/1471-2407/13/79significant relationship between MSI status and histo-
logical subtypes was found.
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